Debu Tripathy
Leads one of the largest breast medical oncology departments, and led the ribociclib trial in premenopausal women.
Debu Tripathy is a breast medical oncologist and editor-in-chief of Cancer. Principal investigator of MONALEESA-7, which showed ribociclib with endocrine therapy improves survival in premenopausal HR+ breast cancer, and a leader in HER2-directed and ADC trials.
| Title | Journal | Year |
|---|---|---|
| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial | Lancet Oncology | 2018 |
| Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer | New England Journal of Medicine | 2019 |
Pages like this
not linked directly; found by shared links- TrialMONALEESA-2
Shares Ribociclib, CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- PersonMariana Chavez-MacGregor
Shares MD Anderson Cancer Center, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonSeock-Ah Im
Shares Ribociclib, CDK4/6, Estrogen receptor (ERα), Triple-negative breast cancer (TNBC).
- PersonGiulio Draetta
Shares CDK4/6, MD Anderson Cancer Center.
- PersonAngela DeMichele
Shares CDK4/6, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonMatthew P. Goetz
Shares CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- PersonDennis J. Slamon
Shares Ribociclib, CDK4/6, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- CompanyCircle Pharma
Shares CDK4/6, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.